About Us
About the COVID-19 Prevention Network (CoVPN)
The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The CoVPN is comprised of the partners listed below.
Our Mission
To conduct Phase 3 efficacy trials for COVID-19 vaccines and monoclonal antibodies. The CoVPN will work to develop and conduct studies to ensure rapid and thorough evaluation of US government-sponsored COVID-19 vaccines and monoclonal antibodies for the prevention of COVID-19 disease.
Partners
If you have questions about the studies, please check the Frequently Asked Questions.
We have clinics all over South Africa, and sites will continue to be added as needed for each study. Different clinics will be running each of the different studies that are coming up in the next several months. Interested in volunteering for a COVID-19 Prevention Clinical Trial? Select the button below for more information about the COVID-19 Clinical Trial and how you can become a volunteer. The COVID-19 Prevention Network does not provide personal medical advice or diagnoses. If you are experiencing a medical emergency, call 911 and notify the operator if you think you might have COVID-19. If you think you have been exposed to COVID-19 and develop a fever and symptoms such as a cough or difficulty breathing, call your healthcare provider immediately for medical advice.
Funding Acknowledgement
This Network is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
CoVPN Operations Centers
c/o CoVPN / HVTN
Hutchinson Center for Research Institute South Africa
New Nurses Home Building, Floor 10
Chris Hani Baragwanath Hospital
Soweto, Johannesburg
South Africa